History of Changes for Study: NCT01287741

A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

A study version is represented by a row in the table.
Select two study versions to compare. One each from columns A and B.
Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
Click "Compare" to do the comparison and show the differences.
Select a version's Submitted Date link to see a rendering of the study for that version.
The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
Hover over the "Recruitment Status" to see how the study's recruitment status changed.
Study edits or deletions are displayed in red.
Study additions are displayed in green.

Study Record Versions

Version	Submitted Date	Changes
1	January 31, 2011	None (earliest Version on record)
2	February 15, 2011	Study Status
3	March 15, 2011	Study Status
4	April 18, 2011	Study Status and Contacts/Locations
5	May 18, 2011	Contacts/Locations, Study Status and Oversight
6	June 15, 2011	Contacts/Locations and Study Status
7	July 19, 2011	Contacts/Locations and Study Status
8	August 10, 2011	Recruitment Status, Contacts/Locations and Study Status
9	September 19, 2011	Contacts/Locations and Study Status
10	October 14, 2011	Contacts/Locations and Study Status
11	November 15, 2011	Contacts/Locations and Study Status
12	December 5, 2011	Study Status and Contacts/Locations
13	January 17, 2012	Contacts/Locations, Study Status and Study Design
14	February 15, 2012	Contacts/Locations, Study Status and Study Design
15	February 16, 2012	Eligibility and Study Status
16	March 16, 2012	Contacts/Locations and Study Status
17	March 22, 2012	Contacts/Locations and Study Status
18	April 18, 2012	Contacts/Locations and Study Status
19	May 3, 2012	Study Status, Contacts/Locations, Eligibility, Study Description and Study Identification
20	May 21, 2012	Contacts/Locations and Study Status
21	June 4, 2012	Contacts/Locations, Study Status, Eligibility, Sponsor/Collaborators and Study Identification
22	July 5, 2012	Contacts/Locations, Study Status and Sponsor/Collaborators
23	July 17, 2012	Contacts/Locations and Study Status
24	August 15, 2012	Contacts/Locations and Study Status
25	September 19, 2012	Contacts/Locations and Study Status
26	October 10, 2012	Contacts/Locations and Study Status
27	November 1, 2012	Contacts/Locations and Study Status
28	November 15, 2012	Contacts/Locations and Study Status
29	December 3, 2012	Contacts/Locations and Study Status
30	January 3, 2013	Contacts/Locations and Study Status
31	January 7, 2013	Contacts/Locations and Study Status
32	January 14, 2013	Contacts/Locations and Study Status
33	January 21, 2013	Contacts/Locations and Study Status
34	January 31, 2013	Contacts/Locations and Study Status
35	February 4, 2013	Contacts/Locations and Study Status
36	February 11, 2013	Contacts/Locations and Study Status
37	February 19, 2013	Contacts/Locations and Study Status
38	February 25, 2013	Contacts/Locations and Study Status
39	March 4, 2013	Contacts/Locations and Study Status
40	March 11, 2013	Contacts/Locations and Study Status
41	March 18, 2013	Contacts/Locations and Study Status
42	March 25, 2013	Contacts/Locations and Study Status
43	April 1, 2013	Contacts/Locations and Study Status
44	April 8, 2013	Contacts/Locations and Study Status
45	April 15, 2013	Contacts/Locations and Study Status
46	April 22, 2013	Contacts/Locations and Study Status
47	April 29, 2013	Contacts/Locations and Study Status
48	May 7, 2013	Contacts/Locations and Study Status
49	May 13, 2013	Contacts/Locations and Study Status
50	July 1, 2013	Contacts/Locations and Study Status
51	July 9, 2013	Contacts/Locations and Study Status
52	July 16, 2013	Contacts/Locations and Study Status
53	July 23, 2013	Contacts/Locations and Study Status
54	July 29, 2013	Contacts/Locations and Study Status
55	August 5, 2013	Contacts/Locations and Study Status
56	August 13, 2013	Contacts/Locations and Study Status
57	August 19, 2013	Contacts/Locations and Study Status
58	August 26, 2013	Contacts/Locations and Study Status
59	September 4, 2013	Study Status and Contacts/Locations
60	September 9, 2013	Contacts/Locations and Study Status
61	September 12, 2013	Contacts/Locations and Study Status
62	September 18, 2013	Contacts/Locations and Study Status
63	September 25, 2013	Contacts/Locations and Study Status
64	October 7, 2013	Study Status and Contacts/Locations
65	October 8, 2013	Contacts/Locations and Study Status
66	October 17, 2013	Contacts/Locations and Study Status
67	October 21, 2013	Contacts/Locations and Study Status
68	October 28, 2013	Contacts/Locations and Study Status
69	November 4, 2013	Contacts/Locations and Study Status
70	November 13, 2013	Contacts/Locations and Study Status
71	November 18, 2013	Contacts/Locations and Study Status
72	November 25, 2013	Contacts/Locations and Study Status
73	December 3, 2013	Contacts/Locations and Study Status
74	December 9, 2013	Contacts/Locations and Study Status
75	December 17, 2013	Contacts/Locations and Study Status
76	January 6, 2014	Contacts/Locations and Study Status
77	January 13, 2014	Contacts/Locations and Study Status
78	January 20, 2014	Contacts/Locations, Arms and Interventions, Sponsor/Collaborators and Study Status
79	January 27, 2014	Contacts/Locations and Study Status
80	February 3, 2014	Contacts/Locations and Study Status
81	February 10, 2014	Contacts/Locations and Study Status
82	February 17, 2014	Contacts/Locations, Sponsor/Collaborators and Study Status
83	February 24, 2014	Contacts/Locations and Study Status
84	March 3, 2014	Contacts/Locations and Study Status
85	March 14, 2014	Contacts/Locations and Study Status
86	March 17, 2014	Contacts/Locations and Study Status
87	March 24, 2014	Contacts/Locations and Study Status
88	March 31, 2014	Contacts/Locations and Study Status
89	April 7, 2014	Study Status and Contacts/Locations
90	April 14, 2014	Contacts/Locations and Study Status
91	April 22, 2014	Contacts/Locations and Study Status
92	April 28, 2014	Contacts/Locations and Study Status
93	May 5, 2014	Study Status and Contacts/Locations
94	May 12, 2014	Contacts/Locations and Study Status
95	May 19, 2014	Contacts/Locations and Study Status
96	May 26, 2014	Contacts/Locations and Study Status
97	June 23, 2014	Contacts/Locations, Study Status and Study Description
98	June 30, 2014	Contacts/Locations and Study Status
99	July 7, 2014	Study Status and Contacts/Locations
100	July 14, 2014	Contacts/Locations and Study Status
101	July 21, 2014	Contacts/Locations and Study Status
102	August 4, 2014	Recruitment Status, Study Status, Contacts/Locations and Study Design
103	August 11, 2014	Study Status
104	August 26, 2014	Arms and Interventions and Study Status
105	September 22, 2014	Study Status
106	October 6, 2014	Study Status
107	October 13, 2014	Study Status
108	October 20, 2014	Study Status
109	November 3, 2014	Contacts/Locations and Study Status
110	November 10, 2014	Contacts/Locations and Study Status
111	November 17, 2014	Study Status
112	November 24, 2014	Contacts/Locations and Study Status
113	December 1, 2014	Study Status
114	December 8, 2014	Contacts/Locations and Study Status
115	December 15, 2014	Contacts/Locations and Study Status
116	December 23, 2014	Contacts/Locations and Study Status
117	January 6, 2015	Study Status
118	January 12, 2015	Contacts/Locations, Study Description and Study Status
119	January 19, 2015	Contacts/Locations, Study Description and Study Status
120	February 5, 2015	Study Status, Contacts/Locations and Study Description
121	February 19, 2015	Study Status
122	February 23, 2015	Study Status
123	March 2, 2015	Study Status
124	March 9, 2015	Contacts/Locations and Study Status
125	March 16, 2015	Study Status
126	April 2, 2015	Contacts/Locations and Study Status
127	May 5, 2015	Study Status
128	May 11, 2015	Contacts/Locations and Study Status
129	May 29, 2015	Study Status
130	June 1, 2015	Study Status
131	July 1, 2015	Study Status
132	July 31, 2015	Contacts/Locations and Study Status
133	August 17, 2015	Study Status
134	October 20, 2016	Arms and Interventions, Outcome Measures, Contacts/Locations, Study Status, Study Identification, Eligibility, Conditions and Study Description
135	August 15, 2017	Study Status, Contacts/Locations, Outcome Measures, Arms and Interventions, Results and Eligibility
136	November 9, 2017	Study Status and Contacts/Locations
137	February 20, 2018	Recruitment Status, Contacts/Locations and Study Status
138	April 24, 2018	Contacts/Locations and Study Status
139	May 9, 2018	Study Status and Contacts/Locations
140	July 30, 2018	Contacts/Locations and Study Status
141	April 8, 2019	Recruitment Status, Outcome Measures, Adverse Events, Study Status, Participant Flow, Baseline Characteristics and Contacts/Locations

Comparison Format:

Merged
Side-by-Side

Study Identification


Unique Protocol ID:	BO21005
Brief Title:	A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Official Title:	A Phase III, Multicenter, Open-label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)
Secondary IDs:	2010-024194-39

Study Status


Record Verification:	August 2013
Overall Status:	Recruiting
Study Start:	July 2011
Primary Completion:	May 2016 [Anticipated]
Study Completion:	May 2016 [Anticipated]

First Submitted:	January 31, 2011
First Submitted that Met QC Criteria:	January 31, 2011
First Posted:	February 1, 2011 [Estimate]

Last Update Submitted that Met QC Criteria:	August 26, 2013
Last Update Posted:	August 27, 2013 [Estimate]

Sponsor/Collaborators


Sponsor:	Hoffmann-La Roche
Responsible Party:	Sponsor
Collaborators:	Fondazione Italiana Linfomi - ETS

Oversight


U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring:

Study Description

Brief Summary:

This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with CHOP chemotherapy versus MabThera/Rituxan (rituximab) with CHOP in previously untreated patients with CD20-positive diffuse large B-cell lymphoma. Patients will be randomized to receive either obinutuzumab 1000 mg intravenously (iv) every 21 days or MabThera/Rituxan 375 mg/m2 iv every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) iv every 21 days. Anticipated time on study treatment is 24 weeks.

Detailed Description:

Conditions


Conditions:	Lymphoma, B-Cell
Keywords:

Study Design


Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 3
Interventional Study Model:	Parallel Assignment
Number of Arms:	2
Masking:	None (Open Label)
Allocation:	Randomized
Enrollment:	1400 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions
Experimental: G-CHOP	Drug: RO5072759 1000 mg iv every 21 days, 8 cycles (additional doses Days 8 and 15 of Cycle 1) Other Names: GA101 Drug: CHOP chemotherapy CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) iv every 21 days, 6 or 8 cycles
Active Comparator: R-CHOP	Drug: rituximab [MabThera/Rituxan] 375 mg/m2 iv every 21 days, 8 cycles Drug: CHOP chemotherapy CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) iv every 21 days, 6 or 8 cycles

Outcome Measures


Primary Outcome Measures:
1.	Progression-free survival, assessed by the investigator according to a modified version of the Revised Response Criteria for Malignant Lymphoma [ Time Frame: up to approximately 78 months ]
Secondary Outcome Measures:
1.	Overall survival [ Time Frame: up to approximately 78 months ]
2.	Overall response rate at the end of treatment, assessed by the investigator and the Independent Review Committee (IRC) [ Time Frame: 24 weeks ]
3.	Complete response rate at the end of treatment, assessed by investigator and IRC [ Time Frame: 24 weeks ]
4.	Progression-free survival assessed by the Independent Review Committee [ Time Frame: up to approximately 78 months ]
5.	Event-free survival, defined as time to progression or relapse, or initiation of non-protocol-specified anti-lymphoma therapy, or death, whichever occurs first [ Time Frame: up to approximately 78 months ]
6.	Disease-free survival, assessed by investigator [ Time Frame: up to approximately 78 months ]
7.	Duration of response, assessed by the investigator [ Time Frame: up to approximately 78 months ]
8.	Time to next lymphoma treatment [ Time Frame: up to approximately 78 months ]
9.	Safety: Incidence of adverse events [ Time Frame: up to approximately 78 months ]
10.	Quality of life (Functional Assessment of Cancer Therapy-Lymphoma subscale, Euro-Quality of Life 5D questionnaire, European Organization for Research and Treatment of Cancer Quality of Life Core 30) [ Time Frame: up to approximately 78 months ]
11.	Medical resource utilization (hospitalizations, drug therapies, medical and surgical procedures and treatments) [ Time Frame: up to approximately 78 months ]

Eligibility


Minimum Age:	18 Years
Maximum Age:
Sex:	All
Gender Based:
Accepts Healthy Volunteers:	No
Criteria:	Inclusion Criteria: Adult patients, >/= 18 years of age Previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) At least 1 bi-dimensionally measurable lesion (>1.5 cm in is largest dimension on the CT scan) Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 Adequate hematological function Low-intermediate, intermediate or high-risk IPI score (low-risk IPI score: IPI 1 irrespective of bulky disease or IPI 0 with bulky disease, defined as one lesion >/= 7.5 cm) Exclusion Criteria: History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines Patients with transformed lymphoma and patients with follicular lymphoma IIIB Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation Prior treatment with cytotoxic drugs or rituximab for another condition (e.g., rheumatoid arthritis) or prior use of an anti-CD20 antibody Prior use of any monoclonal antibody within 3 months of the start of Cycle 1 Ongoing corticosteroid use of > 30 mg/day of prednisone or equivalent Primary CNS lymphoma, blastic variant of mantle-cell lymphoma, or histologic evidence of transformation to a Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, and primary cutaneous DLBCL Positive for HIV Active hepatitis B or C infection

Contacts/Locations


Central Contact Person:	Reference Study ID Number: BO21005 www.roche.com/about_roche/roche_worldwide.htm Telephone: 888-662-6728 (U.S. Only) Email: global.rochegenentechtrials@roche.com
Study Officials:	Clinical Trials Study Director Hoffmann-La Roche
Locations:	United States, Alabama
	[Not yet recruiting] Birmingham, Alabama, United States, 35291-3300
	United States, Arizona
	[Completed] Chandler, Arizona, United States, 85224
	[Recruiting] Tucson, Arizona, United States, 85704
	United States, California
	[Not yet recruiting] Encinitas, California, United States, 92008
	[Recruiting] Encinitas, California, United States, 92024
	[Terminated] Los Angeles, California, United States, 90095-6984
	United States, Colorado
	[Recruiting] Aurora, Colorado, United States, 80012
	United States, Florida
	[Not yet recruiting] Fort Myers, Florida, United States, 33916
	[Not yet recruiting] St Petersburg, Florida, United States, 33719
	United States, Georgia
	[Active, not recruiting] Macon, Georgia, United States, 31201
	United States, Illinois
	[Recruiting] Galesburg, Illinois, United States, 61401
	[Recruiting] Joliet, Illinois, United States, 60435
	[Recruiting] Niles, Illinois, United States, 60714
	[Recruiting] Urbana, Illinois, United States, 61801
	United States, Maine
	[Completed] Portland, Maine, United States, 04102
	United States, Minnesota
	[Recruiting] Saint Louis Park, Minnesota, United States, 55426
	[Recruiting] Woodbury, Minnesota, United States, 55125
	United States, New York
	[Recruiting] Albany, New York, United States, 12206
	United States, North Carolina
	[Terminated] Charlotte, North Carolina, United States, 28204
	[Recruiting] Winston-Salem, North Carolina, United States, 27103
	United States, Ohio
	[Terminated] Middletown, Ohio, United States, 45042
	[Completed] Sandusky, Ohio, United States, 44870
	United States, Oregon
	[Recruiting] Springfield, Oregon, United States, 97477
	United States, South Carolina
	[Not yet recruiting] Charleston, South Carolina, United States, 29524
	[Recruiting] Columbia, South Carolina, United States, 29210
	United States, Tennessee
	[Active, not recruiting] Chattanooga, Tennessee, United States, 37404
	[Recruiting] Nashville, Tennessee, United States, 37203
	United States, Texas
	[Recruiting] Amarillo, Texas, United States, 79106
	[Recruiting] Fort Worth, Texas, United States, 76104
	[Recruiting] Houston, Texas, United States, 77030
	[Recruiting] New Braunfels, Texas, United States, 78130
	United States, Virginia
	[Recruiting] Christiansburg, Virginia, United States, 24073
	[Recruiting] Richmond, Virginia, United States, 23230
	[Recruiting] Winchester, Virginia, United States, 22601
	United States, Washington
	[Active, not recruiting] Tacoma, Washington, United States, 98405
	[Recruiting] Wenatchee, Washington, United States, 98801-0489
	Argentina
	[Not yet recruiting] Cordoba, Argentina, X5003DCE
	[Not yet recruiting] Rosario, Argentina, 2000
	[Recruiting] Rosario, Argentina, S2000DSV
	Australia, Queensland
	[Completed] Cairns, Queensland, Australia, 4870
	Australia, Victoria
	[Recruiting] Frankston, Victoria, Australia, 3199
	[Active, not recruiting] Melbourne, Victoria, Australia, 3168
	Australia, Western Australia
	[Recruiting] Perth, Western Australia, Australia, 6000
	Austria
	[Not yet recruiting] Innsbruck, Austria, 6020
	[Recruiting] Salzburg, Austria, 5020
	[Recruiting] Wien, Austria, 1090
	Brazil, RS
	[Not yet recruiting] Porto Alegre, RS, Brazil, 90035-903
	[Not yet recruiting] Porto Alegre, RS, Brazil, 90110-270
	[Not yet recruiting] Porto Alegre, RS, Brazil, 90610-000
	Brazil, SC
	[Not yet recruiting] Florianopolis, SC, Brazil, 88034-000
	Brazil, SP
	[Not yet recruiting] Campinas, SP, Brazil, 13083-872
	[Not yet recruiting] Sao Paulo, SP, Brazil, 01236-030
	[Not yet recruiting] Sao Paulo, SP, Brazil, 01308-050
	[Not yet recruiting] Sao Paulo, SP, Brazil, 04039-901
	[Not yet recruiting] Sao Paulo, SP, Brazil, 05403-000
	[Not yet recruiting] Sao Paulo, SP, Brazil, 08270-070
	Canada, Alberta
	[Recruiting] Calgary, Alberta, Canada, T2N 4N2
	[Recruiting] Edmonton, Alberta, Canada, T6G 1Z2
	Canada, British Columbia
	[Recruiting] Vancouver, British Columbia, Canada, V5Z 4E6
	Canada, Nova Scotia
	[Recruiting] Halifax, Nova Scotia, Canada, B3H 2Y9
	Canada, Ontario
	[Recruiting] Ottawa, Ontario, Canada, K1H 8L6
	[Recruiting] Toronto, Ontario, Canada, M2K 1E1
	[Recruiting] Toronto, Ontario, Canada, M5G 2M9
	[Completed] Toronto, Ontario, Canada, M9N 1N8
	Canada, Quebec
	[Active, not recruiting] Montreal, Quebec, Canada, H1T 2M4
	[Recruiting] Montreal, Quebec, Canada, H2L 4M1
	[Recruiting] Montreal, Quebec, Canada, H3A 1A1
	[Recruiting] Montreal, Quebec, Canada, H3T 1E2
	[Recruiting] Quebec City, Quebec, Canada, G1J 1Z4
	[Recruiting] Rimouski, Quebec, Canada, G5L 5T1
	Canada, Saskatchewan
	[Active, not recruiting] Saskatoon, Saskatchewan, Canada, S7N 4H4
	China
	[Recruiting] Beijing, China, 100021
	[Recruiting] Beijing, China, 100034
	[Recruiting] Beijing, China, 100071
	[Recruiting] Beijing, China, 100142
	[Not yet recruiting] Beijing, China, 100730
	[Recruiting] Beijing, China, 100853
	[Recruiting] Changchun, China, 130021
	[Recruiting] Changsha, China, 410013
	[Recruiting] Fuzhou, China, 350001
	[Recruiting] Fuzhou, China, 350014
	[Active, not recruiting] Guangzhou, China, 510060
	[Recruiting] Guangzhou, China, 510080
	[Recruiting] Hangzhou, China, 310003
	[Recruiting] Harbin, China, 150081
	[Recruiting] Jiangsu, China, 210009
	[Recruiting] Nanchang City, China, 330006
	[Recruiting] Nanjing, China, 210029
	[Recruiting] Nanning, China, 530021
	[Recruiting] Shanghai, China, 200025
	[Recruiting] Shanghai, China, 200032
	[Recruiting] Shanghai, China, 200433
	[Not yet recruiting] Shenyang, China, 110001
	[Recruiting] Suzhou, China, 215004
	[Recruiting] Suzhou, China, 215006
	[Not yet recruiting] Tianjin, China, 300060
	[Recruiting] Wuhan, China, 430022
	[Recruiting] Wuhan, China, 430023
	[Recruiting] Xian, China, 710000
	Colombia
	[Not yet recruiting] Bogota, Colombia
	[Not yet recruiting] Floridablanca, Colombia
	Czech Republic
	[Recruiting] Brno, Czech Republic, 625 00
	[Recruiting] Hradec Kralove, Czech Republic, 500 05
	[Recruiting] Praha 2, Czech Republic, 128 08
	Denmark
	[Recruiting] København, Denmark, 2100
	[Recruiting] Roskilde, Denmark, 4000
	[Recruiting] Århus, Denmark, 8000
	Germany
	[Recruiting] Aachen, Germany, 52074
	[Recruiting] Berlin, Germany, 10707
	[Active, not recruiting] Dresden, Germany, 01307
	[Active, not recruiting] Erlangen, Germany, 91054
	[Not yet recruiting] Giessen, Germany, 35392
	[Recruiting] Heidelberg, Germany, 69120
	[Recruiting] Wuerzburg, Germany, 97080
	Hong Kong
	[Recruiting] Hong Kong, Hong Kong
	Hungary
	[Recruiting] Budapest, Hungary, 1083
	[Recruiting] Budapest, Hungary, 1097
	[Recruiting] Budapest, Hungary, 1122
	[Recruiting] Debrecen, Hungary, 4032
	[Recruiting] Gyor, Hungary, 9024
	[Recruiting] Kaposvar, Hungary, 7400
	[Completed] Pecs, Hungary, 7624
	[Recruiting] Szeged, Hungary, 6720
	Italy
	[Recruiting] Alessandria, Italy, 15100
	[Not yet recruiting] Bari, Italy, 70124
	[Recruiting] Bologna, Italy, 40138
	[Recruiting] Brescia, Italy, 25123
	[Active, not recruiting] Catania, Italy, 95124
	[Active, not recruiting] Firenze, Italy, 50141
	[Recruiting] Genova, Italy, 16132
	[Not yet recruiting] Ivrea, Italy, 10015
	[Recruiting] Messina, Italy, 98165
	[Active, not recruiting] Milano, Italy, 20132
	[Active, not recruiting] Milano, Italy, 20133
	[Recruiting] Milano, Italy, 20141
	[Not yet recruiting] Napoli, Italy, 80131
	[Active, not recruiting] Napoli, Italy, 80131
	[Active, not recruiting] Novara, Italy, 28100
	[Recruiting] Orbassano, Italy, 10043
	[Not yet recruiting] Pagani (Sa), Italy, 84016
	[Recruiting] Pavia, Italy, 27100
	[Recruiting] Pisa, Italy, 56100
	[Not yet recruiting] Potenza, Italy, 85100
	[Active, not recruiting] Reggio Calabria, Italy, 89100
	[Active, not recruiting] Reggio Emilia, Italy, 42100
	[Active, not recruiting] Roma, Italy, 00161
	[Recruiting] San Giovanni Rotondo, Italy, 71013
	[Recruiting] Terni, Italy, 05100
	[Active, not recruiting] Torino, Italy, 10126
	[Not yet recruiting] Treviso, Italy, 31100
	[Recruiting] Tricase - Le, Italy, 73039
	[Active, not recruiting] Udine, Italy, 33100
	[Active, not recruiting] Verona, Italy, 37130
	[Recruiting] Vicenza, Italy, 36100
	Japan
	[Active, not recruiting] Aichi, Japan, 466-8650
	[Active, not recruiting] Chiba, Japan, 260-8670
	[Active, not recruiting] Fukuoka, Japan, 812-8582
	[Active, not recruiting] Fukuoka, Japan, 830-0011
	[Active, not recruiting] Gifu, Japan, 501-1194
	[Recruiting] Hokkaido, Japan, 060-8648
	[Recruiting] Iwate, Japan, 020-8505
	[Active, not recruiting] Kanagawa, Japan, 236-0004
	[Active, not recruiting] Kyoto, Japan, 606-8507
	[Active, not recruiting] Okayama, Japan, 710-8602
	[Recruiting] Osaka, Japan, 545-8586
	[Active, not recruiting] Osaka, Japan, 565-0871
	[Active, not recruiting] Osaka, Japan, 589-8511
	[Active, not recruiting] Tokyo, Japan, 104-0045
	[Active, not recruiting] Tokyo, Japan, 105-8470
	[Recruiting] Tokyo, Japan, 113-8603
	[Active, not recruiting] Tokyo, Japan, 135-8550
	Korea, Republic of
	[Recruiting] Hwasun, Korea, Republic of, 519-809
	[Recruiting] Kyunggi-do, Korea, Republic of, 410-769
	[Active, not recruiting] Seoul, Korea, Republic of, 110744
	[Recruiting] Seoul, Korea, Republic of, 120-752
	[Recruiting] Seoul, Korea, Republic of, 135-710
	[Recruiting] Seoul, Korea, Republic of, 137-701
	[Recruiting] Seoul, Korea, Republic of, 138-736
	Mexico
	[Not yet recruiting] Chihuahua, Mexico, 31000
	[Not yet recruiting] Guadalajara, Mexico, 44340
	[Not yet recruiting] Monterrey, Mexico, 64460
	[Not yet recruiting] Oaxaca, Mexico, 68000
	[Not yet recruiting] Queretaro, Mexico, 76000
	Peru
	[Not yet recruiting] Lima, Peru, 34
	[Not yet recruiting] Lima, Peru, 41
	[Not yet recruiting] Lima, Peru, Lima 41
	Poland
	[Recruiting] Brzozów, Poland, 36-200
	[Recruiting] Gdansk, Poland, 80-952
	[Recruiting] Lodz, Poland, 93-510
	[Recruiting] Warszawa, Poland, 02-781
	[Recruiting] Wroclaw, Poland, 50-367
	Russian Federation
	[Recruiting] Kazan, Russian Federation, 420029
	[Recruiting] Moscow, Russian Federation, 115478
	[Active, not recruiting] Nizhny Novgorod, Russian Federation, 603126
	[Recruiting] Penza, Russian Federation, 440071
	[Recruiting] Petrozavodsk, Russian Federation, 185019
	[Recruiting] St Petersburg, Russian Federation, 191024
	Serbia
	[Recruiting] Belgrade, Serbia, 11000
	[Active, not recruiting] Novi Sad, Serbia, 21000
	Slovakia
	[Recruiting] Bratislava, Slovakia, 833 10
	South Africa
	[Recruiting] Cape Town, South Africa, 7800
	[Active, not recruiting] Groenkloof, South Africa, 0181
	[Recruiting] Johannesburg, South Africa, 2193
	[Recruiting] Johannesburg, South Africa, 2196
	[Active, not recruiting] Pretoria, South Africa, 0044
	Spain
	[Active, not recruiting] Barcelona, Spain, 08003
	[Active, not recruiting] Barcelona, Spain, 08035
	[Recruiting] Barcelona, Spain, 08036
	[Active, not recruiting] Barcelona, Spain, 08907
	[Active, not recruiting] Madrid, Spain, 28034
	[Terminated] Pontevedra, Spain, 36002
	[Recruiting] Sevilla, Spain, 41009
	[Recruiting] Toledo, Spain, 45004
	Spain, Navarra
	[Active, not recruiting] Pamplona, Navarra, Spain, 31008
	Spain, Tarragona
	[Terminated] Reus, Tarragona, Spain, 43204
	Switzerland
	[Active, not recruiting] Aarau, Switzerland, 5001
	[Recruiting] Bellinzona, Switzerland, 6500
	[Recruiting] Chur, Switzerland, 7000
	[Recruiting] Zürich, Switzerland, 8091
	Taiwan
	[Recruiting] Taipei, Taiwan, 00112
	[Recruiting] Taipei, Taiwan, 100
	[Recruiting] Taipei, Taiwan, 112
	[Recruiting] Taoyuan, Taiwan, 333
	Thailand
	[Recruiting] Bangkok, Thailand, 10330
	[Recruiting] Bangkok, Thailand, 10400
	[Active, not recruiting] Bangkok, Thailand, 10700
	[Active, not recruiting] Khon Kaen, Thailand, 40002
	United Kingdom
	[Recruiting] Aberdeen, United Kingdom, AB25 2ZN
	[Recruiting] Birmingham, United Kingdom, B9 5SS
	[Recruiting] Cambridge, United Kingdom, CB2 0QQ
	[Recruiting] Leicester, United Kingdom, LE1 5WW
	[Recruiting] Wolverhampton, United Kingdom, WV10 0QP

IPDSharing


Plan to Share IPD:

References


Links:
Available IPD/Information: